Status:
COMPLETED
A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Eligibility:
All Genders
18+ years
Brief Summary
This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of sy...
Eligibility Criteria
Inclusion
- Work in cardiology, internal medicine, or nephrology department
- Specialize in one of the following: coronary interventional cardiology, HF, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology
- Practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist
- Manage at least 20 adult patients with ASCVD and CKD (not dialysis-only) every month
Exclusion
- Unwilling to provide informed consent
- Insufficient number of patients with ASCVD and CKD
- Do not fulfil inclusion criteria.
Key Trial Info
Start Date :
September 9 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 5 2024
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT06589791
Start Date
September 9 2024
End Date
December 5 2024
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Shanghai Pharmaceuticals Co., Ltd
Shanghai, China